OBJECTIVES: To characterize HIV-specific cytotoxic T-lymphocyte (CTL) activities in HIV-2-infected individuals and to relate these to HIV-2 proviral load. METHODS: Peripheral blood mononuclear cells were collected from 16 HIV-2-seropositive and four HIV-1/2 dually seropositive subjects. CTL were restimulated with autologous phytohaemagglutinin-stimulated blasts and CTL activities in 'bulk' cultures were evaluated 7 and 14 days later by a standard 51Cr-release assay using autologous B-cell lines infected with recombinant vaccinia expressing HIV-2 Gag, Pol or Nef protein. Proviral load was quantified by polymerase chain reaction (PCR) which used HIV-2 long terminal repeat primers and an external standard control made by an HIV-2CBL-22 chronically infected C8166 cell line. A biotinylated primer was used to capture the 35S dATP-incorporated secondary PCR product in a quantitative radiometric assay. RESULTS: After 14 days of culture CTL responses against Gag or Pol protein were seen in 18 (90.0%) and 14 (70.0%) out of 20 subjects, respectively, whereas a CTL response was noted against Nef protein in five (25.0%) out of 20 subjects. In 14 (70.0%) out of 20 subjects multiple HIV proteins were simultaneously recognized. The sum of specific lysis (%) against HIV-2 Gag, Pol and Nef at 30:1 effector-to-target ratio, or specific lysis of the dominant CTL response, correlated strongly with HIV-2 proviral load expressed as copies per 10(5) CD4+ cells (r = -0.625, P = 0.003 and r = -0.674, P = 0.001, respectively). CONCLUSION: HIV-2-specific CTL to multiple gene products was demonstrated in most HIV-2-infected individuals. An inverse correlation between the level of CTL activity and proviral load was found, which supports the hypothesis that CTL are important in the control of HIV-2 replication.
OBJECTIVES: To characterize HIV-specific cytotoxic T-lymphocyte (CTL) activities in HIV-2-infected individuals and to relate these to HIV-2 proviral load. METHODS: Peripheral blood mononuclear cells were collected from 16 HIV-2-seropositive and four HIV-1/2 dually seropositive subjects. CTL were restimulated with autologous phytohaemagglutinin-stimulated blasts and CTL activities in 'bulk' cultures were evaluated 7 and 14 days later by a standard 51Cr-release assay using autologous B-cell lines infected with recombinant vaccinia expressing HIV-2 Gag, Pol or Nef protein. Proviral load was quantified by polymerase chain reaction (PCR) which used HIV-2 long terminal repeat primers and an external standard control made by an HIV-2CBL-22 chronically infected C8166 cell line. A biotinylated primer was used to capture the 35SdATP-incorporated secondary PCR product in a quantitative radiometric assay. RESULTS: After 14 days of culture CTL responses against Gag or Pol protein were seen in 18 (90.0%) and 14 (70.0%) out of 20 subjects, respectively, whereas a CTL response was noted against Nef protein in five (25.0%) out of 20 subjects. In 14 (70.0%) out of 20 subjects multiple HIV proteins were simultaneously recognized. The sum of specific lysis (%) against HIV-2 Gag, Pol and Nef at 30:1 effector-to-target ratio, or specific lysis of the dominant CTL response, correlated strongly with HIV-2 proviral load expressed as copies per 10(5) CD4+ cells (r = -0.625, P = 0.003 and r = -0.674, P = 0.001, respectively). CONCLUSION:HIV-2-specific CTL to multiple gene products was demonstrated in most HIV-2-infected individuals. An inverse correlation between the level of CTL activity and proviral load was found, which supports the hypothesis that CTL are important in the control of HIV-2 replication.
Authors: D Durali; J Morvan; F Letourneur; D Schmitt; N Guegan; M Dalod; S Saragosti; D Sicard; J P Levy; E Gomard Journal: J Virol Date: 1998-05 Impact factor: 5.103
Authors: G Ferrari; W Humphrey; M J McElrath; J L Excler; A M Duliege; M L Clements; L C Corey; D P Bolognesi; K J Weinhold Journal: Proc Natl Acad Sci U S A Date: 1997-02-18 Impact factor: 11.205
Authors: S Andersson; O Larsen; Z Da Silva; H Linder; H Norrgren; F Dias; R Thorstensson; P Aaby; G Biberfeld Journal: Clin Exp Immunol Date: 2005-03 Impact factor: 4.330
Authors: A Bertoletti; F Cham; S McAdam; T Rostron; S Rowland-Jones; S Sabally; T Corrah; K Ariyoshi; H Whittle Journal: J Virol Date: 1998-03 Impact factor: 5.103
Authors: N N Zheng; N B Kiviat; P S Sow; S E Hawes; A Wilson; H Diallo-Agne; C W Critchlow; G S Gottlieb; L Musey; M J McElrath Journal: J Virol Date: 2004-12 Impact factor: 5.103
Authors: Maarten F Schim van der Loeff; Natasha Larke; Steve Kaye; Neil Berry; Koya Ariyoshi; Abraham Alabi; Carla van Tienen; Aleksandra Leligdowicz; Ramu Sarge-Njie; Zacharias da Silva; Assan Jaye; Dominique Ricard; Tim Vincent; Sarah Rowland Jones; Peter Aaby; Shabbar Jaffar; Hilton Whittle Journal: Retrovirology Date: 2010-05-19 Impact factor: 4.602
Authors: Russell B Foxall; Catarina S Cortesão; Adriana S Albuquerque; Rui S Soares; Rui M M Victorino; Ana E Sousa Journal: J Virol Date: 2008-07-23 Impact factor: 5.103
Authors: X Jin; D E Bauer; S E Tuttleton; S Lewin; A Gettie; J Blanchard; C E Irwin; J T Safrit; J Mittler; L Weinberger; L G Kostrikis; L Zhang; A S Perelson; D D Ho Journal: J Exp Med Date: 1999-03-15 Impact factor: 14.307
Authors: Aleksandra Leligdowicz; Louis-Marie Yindom; Clayton Onyango; Ramu Sarge-Njie; Abraham Alabi; Matthew Cotten; Tim Vincent; Carlos da Costa; Peter Aaby; Assan Jaye; Tao Dong; Andrew McMichael; Hilton Whittle; Sarah Rowland-Jones Journal: J Clin Invest Date: 2007-10 Impact factor: 14.808